Clinical trials: Plaque Psoriasis.
Psoriasis Vulgaris
Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
This was a Phase I, single-center, randomized, controlled trial to evaluate the antipsoriatic efficacy of calcipotriol in novel formulations based on AKVANO technology as compared to marketed calcipotriol products (Daivonex®…
- Trial name
- AKVANO-AKP01 (NCT05488990)
- Testing
- AKVANO-Calcipotriol formulation 1, AKVANO-Calcipotriol formulation 2, AKVANO vehicle formulation 1
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Lipidor AB
Psoriasis
A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
This is an open-label, multicenter study designed to evaluate the efficacy and safety of efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab taper in subjects with plaque psoriasis who…
- Trial name
- NCT00109252
- Testing
- Raptiva (efalizumab)
- Sponsor
- Genentech, Inc.
Effects, Drug Side
An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis in order to select doses for further clinical trials.
- Trial name
- NCT05858047
- Testing
- SYHX1901
- Where
- China
- Volunteers
- 93 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Moderate to Severe Plaque Psoriasis
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of…
- Trial name
- NCT07051538
- Testing
- SHR-1139 Injections
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Plaque Psoriasis
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06176768
- Testing
- LY3972406
- Where
- 12 sites in United States
- Volunteers
- 33 people
- Sponsor
- Eli Lilly and Company
Psoriasis (PsO)
Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients
The goal of this clinical trial] is to learn if SFA002 can treat mild, moderate and severe plaque psoriasis as good or better than Otezla, compared to placebo in adult and pediatric patients.
- Trial name
- NCT06863493
- Testing
- SFA002, Otezla
- Volunteers
- 125 people
- Sponsor
- SFA Therapeutics
Plaque Psoriasis
A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis
The aim of this proof of concept study is to show the safety and efficacy of 0.5 % dermal roflumilast cream in the treatment of plaque psoriasis in adults.
- Trial name
- NCT00746434
- Testing
- Roflumilast cream
- Sponsor
- AstraZeneca
Psoriasis Vulgaris
A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris
The purpose of this study is to evaluate the anti-psoriatic effect of Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes), Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes) compared with…
- Trial name
- NCT01607853
- Testing
- Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes), Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes), Daivobet® gel applied for 24 hours (+/- 2 hours)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Plaque Type Psoriasis
SHP-141C in Plaque Type Psoriasis
The purpose of this study is to assess the safety, tolerability and clinical activity of the SHP-141C topical cream formulations in patients with plaque type psoriasis.
- Trial name
- NCT01646567
- Testing
- SHP-141C, Betamethasone Valerate, Calcipotriol
- Where
- Australia
- Volunteers
- 14 people
- Sponsor
- TetraLogic Pharmaceuticals
Psoriasis, Plaque-type Psoriasis
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
This study is designed to evaluate the proportion of patients achieving reversal of chronic plaque psoriasis at week 4 and 12 following multiple doses of secukinumab administered subcutaneously (sc) compared to placebo.
- Trial name
- NCT01537432
- Testing
- secukinumab
- Where
- 12 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to <18 years with moderate to severe plaque psoriasis.
- Trial name
- NCT04772079
- Testing
- Deucravacitinib
- Where
- 65 sites in Argentina, Australia and 11 more
- Volunteers
- 153 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
This is a randomized double-blind vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults.
- Trial name
- NCT03983980
- Testing
- Tapinarof, Vehicle Cream
- Where
- 50 sites in United States, Canada
- Volunteers
- 515 people
- Sponsor
- Organon and Co
Psoriasis
A 36-Week Extension to Protocol ISA04-03
The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.
- Trial name
- SPIRIT (NCT00258713)
- Testing
- voclosporin
- Where
- 29 sites in Canada
- Volunteers
- 309 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Psoriasis Vulgaris
A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
The purpose of the study is to evaluate the anti-psoriatic effect of LEO 90100 cutaneous spray ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
- Trial name
- NCT01347255
- Testing
- LEO90100 cutaneous spray, ointment, LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate, LEO 90100 cutaneous spray, ointment, vehicle
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis, Plaque Psoriasis
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
- Trial name
- CIMPACT (NCT02346240)
- Testing
- Certolizumab Pegol, Etanercept
- Where
- 70 sites in United States, Bulgaria and 7 more
- Volunteers
- 559 people
- Sponsor
- UCB Biopharma S.P.R.L.
Plaque Psoriasis
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
This is a parallel group, double blind, vehicle-controlled study in which roflumilast (ARQ-151) cream 0.3%, roflumilast cream 0.15%, or vehicle cream is applied once daily (QD) for 84 days to subjects with chronic plaque…
- Trial name
- ARQ-151-201 (NCT03638258)
- Testing
- Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream
- Where
- 30 sites in United States, Canada
- Volunteers
- 331 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Psoriasis
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) =…
- Trial name
- GUIDE (NCT03818035)
- Testing
- Guselkumab
- Where
- 90 sites in France, Germany
- Volunteers
- 880 people
- Sponsor
- Janssen-Cilag International NV
Psoriasis
Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test
The aim of the exploratory study is to compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT).
- Trial name
- NCT01360944
- Testing
- LAS41004, reference
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Almirall, S.A.
Psoriasis
Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population
Secukinumab targets a different interleukin and has potential to be used as alternative to existing treatments. This study will provide clinical data with respect to efficacy through Psoriasis Area and Severity Index (PASI) at 16…
- Trial name
- NCT02795416
- Testing
- "Secukinumab" "Cosentyx TM"
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06108544
- Testing
- TAK-279, Apremilast
- Where
- 217 sites in United States, Argentina and 14 more
- Volunteers
- 1,108 people
- Sponsor
- Takeda